Precipio (PRPO) investor relations material

Executive summary

• Q3 net sales reached a record $7.331M, up 8% YoY; adjusted EBITDA was $0.4M, operating cash flow was $0.6M, and quarter-end cash was $3.576M.

• Management targets a combined annualized exit run rate above $40M at end-2027, while filings state substantial doubt remains about continued operations over the next 12 months.

Financial highlights

• Q3 net sales were $7.331M versus $6.767M YoY; nine-month sales were $21.063M versus $17.350M.

• Q3 gross profit was $3.378M versus $3.005M YoY; operating expenses were $3.376M versus $3.066M. Nine-month expenses rose to $11.264M from $9.318M.

• Q3 operating income was $2K and net loss was $8K; nine-month operating loss was $2.025M and net loss was $1.670M.

• Adjusted EBITDA was $0.4M, consistent with Q2; operating cash flow was $0.6M versus $0.7M in Q2. Cash rose $0.5M in Q3 to $3.576M.

Outlook and guidance

• End-2027 annualized exit run-rate targets are Products above $10M, Pathology Services ~$30M, and combined above $40M; these are not FY revenue forecasts.

• Management said the current product pipeline could support the $10M target if half converts; customer onboarding can take 3–18 months. Quarterly product revenue additions are targeted to rise from ~$100K to $250K–$500K.

• 2027 plans include doubling the four-member commercial sales force, adding marketing and technical support, and increasing conferences, clinical evidence and distributor engagement.

• Management expects quarter-end cash to support faster product commercialization; continued operations over the next 12 months depend on business-plan execution, additional revenue and financing if needed.